Highest-materiality recent filing
ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M
Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.
ImmuCell settles Norbrook dispute, to receive $2M payment
ImmuCell and Norbrook entered a Settlement Deed on May 8, 2026 resolving all claims from a 2019 Development and Supply Agreement.
ImmuCell appoints two new independent directors; three directors retire effective April 15, 2026
Bryan Gathagan, Michael Brigham, and Bobbi Jo Brockmann retire from board effective April 15, 2026.
ImmuCell reports Q1 2026 preliminary sales up 28.4% to $10.4M; Tri-Shield up 38.5%
Total product sales $10.4M vs $8.1M in Q1 2025, a 28.4% increase.
ImmuCell appoints Kathy Turner to board, replacing retiring Steven Rosgen
Steven Rosgen resigns from the board effective April 1, 2026, after 8 years of service.
ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M
Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.
Two ImmuCell directors will not seek re-election at 2026 annual meeting
Steven A. Rosgen and Bryan K. Gathagan will not stand for re-election, citing time constraints from full-time roles.
ImmuCell enters new employment agreements with CFO, SVP; grants stock options
CFO Fiori base salary $315k, target bonus 50% of base, option for 120k shares at $6.26.
ImmuCell reports Q4 sales down 1.6% YoY; records $3.6M impairment, pauses Re-Tain
Q4 total sales $7.6M (-1.6% YoY); domestic sales up 8.7%, international down 52.6%.
ImmuCell pauses Re-Tain after FDA incomplete letter, shifts focus to First Defense; $2.3M impairment
FDA issued Incomplete Letter for Re-Tain NADA on Dec 23 due to contract manufacturer inspection issues; four of five Technical Sections had Complete Letters.
ImmuCell Q3 product sales $5.5M (-8% YoY); net loss narrows to $140k; gross margin recovers to 43%
Product sales Q3 2025: $5.5M, down 8% YoY; nine-month 2025: $20.0M, up 7% YoY.
ImmuCell names Olivier te Boekhorst CEO; board expanded to nine directors
Olivier te Boekhorst started as President and CEO on Nov 1, 2025, succeeding Michael Brigham.
ImmuCell Q3 sales fall 8% to $5.5M; 9-month sales up 7% to $20M
Preliminary Q3 2025 product sales $5.5M vs $6.0M in Q3 2024, an 8% decrease.
ImmuCell appoints Olivier te Boekhorst as President and CEO effective Nov 1, 2025
Olivier te Boekhorst, former IDEXX Senior VP and Archimed Operating Partner, named CEO.
ImmuCell extends $1M line of credit with Maine Community Bank to Sept 2026
$1M line of credit extended through September 11, 2026.
ImmuCell swings to Q2 profit of $502k on 18% sales growth to $6.4M
Q2 product sales $6.4M, up 18% YoY; H1 sales $14.5M, up 14%.
ImmuCell refinances bank debt with $2.3M loan at 6.5%, extending to 2030
New $2,327,119 loan at 6.5% fixed from Maine Community Bank; pays off prior loans at 7% and 8%.
ImmuCell Q2 2025 preliminary sales up 18% YoY to $6.4M; backlog cleared
Preliminary Q2 2025 product sales $6.4M, up 18% from $5.5M in Q2 2024.
ImmuCell CEO Michael Brigham plans retirement by early 2026; board launches succession search
President/CEO Michael Brigham (65) intends to retire from full-time work by early 2026; board has started successor search.
ImmuCell shareholders reject say-on-pay and stock plan increase at 2025 annual meeting
All seven director nominees elected; no director received more than 50% withhold.
ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago
Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).
ImmuCell reports record Q1 2025 sales of $8.1M, up 11% YoY
Preliminary unaudited product sales for Q1 2025: $8.1M, up 11% from $7.3M in Q1 2024.
ImmuCell appoints Timothy C. Fiori as CFO effective April 7, 2025
Fiori served 24 years at IDEXX Laboratories, most recently as Senior Director Finance, Commercial Operations.
ImmuCell Q4 product sales up 52% to $7.8M; net income $515k vs loss year ago
Product sales for Q4 2024 rose 52% to ~$7.8M; full-year sales up 52% to ~$26.5M.
ImmuCell settles insurance claim for $426,587; total recovery $676,587 from contamination events
Settlement of $426,587 received for production contamination losses from late 2022 through April 2024.
ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M
Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).
ImmuCell VP of Manufacturing to retire July 2025; enters separation agreement
Elizabeth L. Williams moves to part-time effective Dec 7, 2024; retires July 1, 2025.
Norbrook will complete manufacture of current in-process inventory.
ImmuCell reports Q3 2024 product sales up 11% to $6M; net loss narrows to $702k
Product sales $6M in Q3 2024 vs $5.4M in Q3 2023 (+11%); 9-month sales $18.7M (+51% YoY).
ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M
Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).
ImmuCell restructures lease payment, deferring $368,743 into monthly installments through July 2025
Fifth Amendment of Lease with TVP, LLC replaces $368,743 lump sum due Jan 2025 with six $20,000 monthly payments (Jan-Jun 2025) and a $248,743 payment in July 2025.
ImmuCell Q2 product sales up 55% but net loss $1.5M; FDA incomplete letter for Re-Tain
Product sales $5.5M (+55% YoY); six-month sales $12.7M (+82% YoY).
ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%
Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.
ImmuCell shareholders elect all 7 directors, approve say-on-pay, ratify auditor
All 7 director nominees elected with 88% or more of votes cast (excluding broker non-votes).
ImmuCell amends lease to defer $488,743 tenant improvement payment over six months
Replaces $488,743 lump-sum rent due July 2024 with $20K/month Jul–Dec 2024 plus $368,743 in Jan 2025.
ImmuCell provides Re-Tain® FDA update; NADA submission after contract manufacturer clearance
Received FDA Incomplete Letter on CMC Technical Section for Re-Tain®; fourth submission prepared.
ImmuCell Q1 2024: Record sales $7.3M (+111% YoY); net loss narrows; FDA delays Re-Tain
Product sales of $7.3M, up 111% YoY from $3.4M; all-time quarterly record.
ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY
Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.
ImmuCell enters ATM offering agreement for up to $11M common stock with Craig-Hallum
Company entered into ATM offering agreement with Craig-Hallum for up to $11M of common stock.
The Board of Directors of ImmuCell Corporation (the Company) has elected Timothy C. Fiori, age 46, to serve as its Chief Financial Officer effective April 7, 2025.
Max materiality 0.85 · Median 0.60 · Most common event earnings